CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its annual financial report. Financial Performance: The company has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share for the entire year. However, it has recognized $370.0 million in collaboration revenue for the year ended December 31, 2023, primarily related to agreements with Vertex Pharmaceuticals. Additionally, grant revenue amounted to $1.2 million. Business Development: CRISPR Therapeutics has made strides in its business development, with the landmark approval of CASGEVY, the world's first CRISPR-based gene-editing therapy, for the treatment of severe SCD or TDT. The company has also advanced multiple gene-edited cell therapy programs for oncology and autoimmune diseases, and initiated Phase 1 clinical trials for...Show More

CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its annual financial report. Financial Performance: The company has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share for the entire year. However, it has recognized $370.0 million in collaboration revenue for the year ended December 31, 2023, primarily related to agreements with Vertex Pharmaceuticals. Additionally, grant revenue amounted to $1.2 million. Business Development: CRISPR Therapeutics has made strides in its business development, with the landmark approval of CASGEVY, the world's first CRISPR-based gene-editing therapy, for the treatment of severe SCD or TDT. The company has also advanced multiple gene-edited cell therapy programs for oncology and autoimmune diseases, and initiated Phase 1 clinical trials for in vivo gene editing programs targeting cardiovascular disease. Future Plans: The company plans to continue expanding its clinical trials, including initiating a trial for CTX112 in systemic lupus erythematosus and expanding trials of CTX131 into hematologic malignancies. It also aims to advance its portfolio of in vivo programs and develop gene-edited stem cell-derived therapies for the treatment of Type 1 Diabetes. CRISPR Therapeutics is focused on innovating next-generation editing modalities through its CRISPR-X research team and establishing internal manufacturing capabilities for clinical and commercial production of its product candidates.